SCHEDULE 13G/A · 2026-11-05
Viking Therapeutics reports FMR LLC's significant stake in its common stock, reflecting ongoing interest in the pharmaceutical preparations sector.
| Name | Viking Therapeutics, Inc. |
|---|---|
| CIK | 0001607678 |
| Tickers | VKTX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Large accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 461073877 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 858-704-4660 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Viking Therapeutics reports FMR LLC's significant stake in its common stock, reflecting ongoing interest in the pharmaceutical preparations sector.
652 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002856 | 005-88828 | 261526319 | 34 | 11706 | |||
| 2026-10-29 | 10-Q | 10-Q | 0001193125-26-436432 | 001-37355 | 261496813 | 34 | 10286519 | 1 | 1 | |
| 2026-10-28 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-436145 | 001-37355 | 261495848 | 34 | 524444 | 1 | 1 |
| 2026-09-28 | 8-K | 8-K | 1.01,2.03,9.01 | 0001193125-26-405580 | 001-37355 | 261418399 | 34 | 3747206 | 1 | 1 |
| 2026-09-25 | 424B5 | 424B5 | 0001193125-26-401385 | 333-297820 | 261406033 | 33 | 1815013 | 1 | 1 | |
| 2026-09-25 | 424B5 | 424B5 | 0001193125-26-401384 | 333-297820 | 261406032 | 33 | 1227246 | 1 | 1 | |
| 2026-09-24 | FWP | FREE WRITING PROSPECTUS | 0001213900-26-102798 | 333-297820 | 261402077 | 34 | 52360 | |||
| 2026-09-24 | 305B2 | APPLICATION FOR DESIGNATION OF A NEW TRUSTEE | 0001213900-26-102782 | 333-297820 | 261402012 | 33 | 458823 | |||
| 2026-09-23 | 424B5 | 424B5 | 0001193125-26-399628 | 333-297820 | 261401662 | 33 | 1629073 | |||
| 2026-09-23 | 424B5 | 424B5 | 0001193125-26-399627 | 333-297820 | 261401661 | 33 | 1074466 | |||
| 2026-09-22 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-397219 | 001-37355 | 261395230 | 34 | 372074 | 1 | 1 |
| 2026-08-07 | 4 | 4 | 0002144542-26-000004 | 7054 | ||||||
| 2026-08-07 | 3 | 3 | 0002144542-26-000003 | 13376 | ||||||
| 2026-07-30 | S-3ASR | S-3ASR | 0001193125-26-324455 | 333-297820 | 261219778 | 33 | 2161995 | 1 | 1 | |
| 2026-07-29 | 4 | 4 | 0001193125-26-324448 | 7179 | ||||||
| 2026-07-29 | 4 | 4 | 0001193125-26-324447 | 7484 | ||||||
| 2026-07-29 | 4 | 4 | 0001193125-26-324446 | 7380 | ||||||
| 2026-07-29 | 10-Q | 10-Q | 0001193125-26-324219 | 001-37355 | 261218930 | 34 | 10074813 | 1 | 1 | |
| 2026-07-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007394 | 001-37355 | 261217806 | 33 | 4712 | |||
| 2026-07-29 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-323652 | 001-37355 | 261217383 | 34 | 462676 | 1 | 1 |
| 2026-07-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007380 | 001-37355 | 261217334 | 33 | 4726 | |||
| 2026-07-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007376 | 001-37355 | 261217310 | 33 | 4729 | |||
| 2026-06-03 | 4 | 4 | 0001193125-26-256039 | 5405 | ||||||
| 2026-06-03 | 3 | 3 | 0001193125-26-256038 | 13248 | ||||||
| 2026-05-26 | 8-K | 8-K | 5.07,9.01 | 0001193125-26-239535 | 001-37355 | 261020718 | 34 | 209288 | 1 | 1 |
| 2026-04-30 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-001179 | 005-88828 | 26923391 | 34 | 7411 | |||
| 2026-04-30 | 10-Q | 10-Q | 0001193125-26-193315 | 001-37355 | 26919568 | 34 | 8502302 | 1 | 1 | |
| 2026-04-29 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-191487 | 001-37355 | 26915804 | 34 | 394226 | 1 | 1 |
| 2026-04-01 | ARS | ARS | 0001193125-26-137931 | 001-37355 | 26828437 | 34 | 1278605 | |||
| 2026-04-01 | DEFA14A | DEFA14A | 0001193125-26-137924 | 001-37355 | 26828377 | 34 | 367068 | |||
| 2026-04-01 | DEF 14A | DEF 14A | 0001193125-26-137915 | 001-37355 | 26828323 | 34 | 4125139 | 1 | 1 | |
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-002541 | 005-88828 | 26805110 | 34 | 7176 | |||
| 2026-03-10 | 4 | 4 | 0001193125-26-100581 | 4407 | ||||||
| 2026-02-11 | 10-K | 10-K | 0001193125-26-046876 | 001-37355 | 26622128 | 34 | 13600726 | 1 | 1 | |
| 2026-02-11 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-046536 | 001-37355 | 26620740 | 34 | 476283 | 1 | 1 |
| 2026-01-26 | 4 | 4 | 0001193125-26-023030 | 5283 | ||||||
| 2026-01-26 | 3 | 3 | 0001193125-26-023025 | 13262 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003116 | 17384 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003115 | 17488 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003113 | 17332 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003112 | 6738 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003111 | 6768 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003110 | 6739 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003109 | 12080 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-003108 | 6761 | ||||||
| 2026-01-05 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000106 | 001-37355 | 26506896 | 33 | 6604 | |||
| 2026-01-05 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000105 | 001-37355 | 26506787 | 33 | 6595 | |||
| 2026-01-05 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000104 | 001-37355 | 26506730 | 33 | 6583 | |||
| 2026-01-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000086 | 001-37355 | 26502957 | 33 | 4680 | |||
| 2025-11-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-002861 | 005-88828 | 251452816 | 34 | 11441 | |||
| 2025-10-28 | 4 | 4 | 0001193125-25-254304 | 7203 | ||||||
| 2025-10-28 | 4 | 4 | 0001193125-25-254300 | 15179 | ||||||
| 2025-10-28 | 4 | 4 | 0001193125-25-254299 | 7187 | ||||||
| 2025-10-28 | 4 | 4 | 0001193125-25-254298 | 7211 | ||||||
| 2025-10-28 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008235 | 001-37355 | 251425363 | 33 | 4702 | |||
| 2025-10-28 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008234 | 001-37355 | 251425323 | 33 | 4705 | |||
| 2025-10-28 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008233 | 001-37355 | 251425198 | 33 | 4677 | |||
| 2025-10-27 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008201 | 001-37355 | 251420183 | 33 | 5894 | |||
| 2025-10-23 | 10-Q | 10-Q | 0001193125-25-247059 | 001-37355 | 251410933 | 34 | 9170896 | 1 | 1 | |
| 2025-10-22 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-246775 | 001-37355 | 251410228 | 34 | 475855 | 1 | 1 |
| 2025-08-19 | 8-K | 8-K | 7.01,9.01 | 0001607678-25-000003 | 001-37355 | 251229635 | 34 | 325555 | 1 | 1 |
| 2025-08-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-002155 | 005-88828 | 251188536 | 34 | 11223 | |||
| 2025-07-23 | 10-Q | 10-Q | 0000950170-25-097950 | 001-37355 | 251143738 | 34 | 9127422 | 1 | 1 | |
| 2025-07-23 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-097885 | 001-37355 | 251143156 | 34 | 465651 | 1 | 1 |
| 2025-07-03 | 4 | 4 | 0000950170-25-093793 | 7070 | ||||||
| 2025-07-03 | 4 | 4 | 0000950170-25-093792 | 7088 | ||||||
| 2025-07-03 | 4 | 4 | 0000950170-25-093791 | 7086 | ||||||
| 2025-07-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004829 | 001-37355 | 251104674 | 33 | 4727 | |||
| 2025-07-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004828 | 001-37355 | 251104651 | 33 | 4730 | |||
| 2025-07-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004825 | 001-37355 | 251104612 | 33 | 4711 | |||
| 2025-05-27 | 8-K | 8-K | 5.07,9.01 | 0000950170-25-077865 | 001-37355 | 25989961 | 34 | 180810 | 1 | 1 |
| 2025-05-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-001596 | 005-88828 | 25933363 | 34 | 11606 | |||
| 2025-04-24 | 10-Q | 10-Q | 0000950170-25-058129 | 001-37355 | 25868176 | 34 | 10058162 | 1 | 1 | |
| 2025-04-23 | DEFA14A | DEFA14A | 0000950170-25-057537 | 001-37355 | 25862795 | 34 | 520962 | |||
| 2025-04-23 | DEFR14A | DEFR14A | 0000950170-25-057535 | 001-37355 | 25862784 | 34 | 3640546 | 1 | 1 | |
| 2025-04-23 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-057337 | 001-37355 | 25861427 | 34 | 402843 | 1 | 1 |
| 2025-04-23 | 8-K | 8-K | 4.01,8.01,9.01 | 0000950170-25-057323 | 001-37355 | 25861333 | 34 | 170747 | 1 | 1 |
| 2025-04-23 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-000430 | 005-88828 | 25859546 | 34 | 11314 | |||
| 2025-04-21 | UPLOAD | filename1.pdf | 0000000000-25-004171 | 001-37355 | 39611 | |||||
| 2025-04-14 | 4 | 4 | 0000950170-25-053867 | 6402 | ||||||
| 2025-04-08 | 4/A | 4/A | 0000950170-25-052255 | 5291 | ||||||
| 2025-04-08 | CORRESP | filename1.htm | 0000950170-25-052253 | 32623 | ||||||
| 2025-04-08 | ARS | ARS | 0000950170-25-052204 | 001-37355 | 25823037 | 34 | 1705138 | |||
| 2025-04-08 | DEFA14A | DEFA14A | 0000950170-25-052198 | 001-37355 | 25823023 | 34 | 514804 | |||
| 2025-04-08 | DEF 14A | DEF 14A | 0000950170-25-052162 | 001-37355 | 25822731 | 34 | 3542603 | 1 | 1 | |
| 2025-04-02 | 4 | 4 | 0000950170-25-049717 | 4368 | ||||||
| 2025-03-31 | UPLOAD | filename1.pdf | 0000000000-25-003431 | 001-37355 | 44166 | |||||
| 2025-03-11 | 8-K | 8-K | 1.01,2.03,8.01,9.01 | 0000950170-25-036820 | 001-37355 | 25725831 | 34 | 227695 | 1 | 1 |
| 2025-02-26 | 10-K | 10-K | 0000950170-25-027824 | 001-37355 | 25670673 | 34 | 13524207 | 1 | 1 | |
| 2025-02-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-014464 | 001-37355 | 25593302 | 34 | 480316 | 1 | 1 |
| 2025-02-04 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-25-000647 | 005-88828 | 25587844 | 34 | 12086 | |||
| 2025-01-06 | 4 | 4 | 0000950170-25-002487 | 13004 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002486 | 13017 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002485 | 13207 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002484 | 4994 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002483 | 4964 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002482 | 4965 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002481 | 4970 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002480 | 4988 | ||||||
| 2025-01-06 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-000164 | 001-37355 | 25512514 | 33 | 6573 | |||
| 2025-01-06 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-000163 | 001-37355 | 25512426 | 33 | 6577 | |||
| 2025-01-06 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-000162 | 001-37355 | 25512329 | 33 | 6557 | |||
| 2024-11-14 | SC 13G/A | sayw24111431_13ga.htm | 0000905148-24-003164 | 005-88828 | 241463160 | 34 | 404810 | |||
| 2024-11-12 | SC 13G/A | UnitedStates_13G__VikingTher.txt | 0000932471-24-001267 | 005-88828 | 241450273 | 34 | 6569 | |||
| 2024-11-08 | 4 | 4 | 0000950170-24-124296 | 7836 | ||||||
| 2024-11-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-008355 | 001-37355 | 241442394 | 33 | 4704 | |||
| 2024-11-04 | SC 13G/A | UnitedStates_13G__VikingTher.txt | 0000932471-24-000703 | 005-88828 | 241422449 | 34 | 5607 | |||
| 2024-11-04 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-120267 | 001-37355 | 241420692 | 34 | 340386 | 1 | 1 |
| 2024-10-28 | 4 | 4 | 0000950170-24-117885 | 33517 | ||||||
| 2024-10-28 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-007913 | 001-37355 | 241401397 | 33 | 7264 | |||
| 2024-10-25 | 4 | 4 | 0000950170-24-117514 | 8158 | ||||||
| 2024-10-25 | 4 | 4 | 0000950170-24-117513 | 8132 | ||||||
| 2024-10-25 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000082 | 001-37355 | 241397171 | 33 | 4356 | |||
| 2024-10-25 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000081 | 001-37355 | 241397030 | 33 | 6739 | |||
| 2024-10-23 | 10-Q | 10-Q | 0000950170-24-116708 | 001-37355 | 241389720 | 34 | 8092474 | 1 | 1 | |
| 2024-10-23 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-116642 | 001-37355 | 241389314 | 34 | 442975 | 1 | 1 |
| 2024-10-18 | SC 13G/A | Viking_Therapeutics_Inc.htm | 0000093751-24-000891 | 005-88828 | 241379619 | 34 | 56005 | |||
| 2024-09-20 | 4 | 4 | 0000950170-24-108577 | 8132 | ||||||
| 2024-09-20 | 4 | 4 | 0000950170-24-108576 | 12908 | ||||||
| 2024-09-20 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000077 | 001-37355 | 241313737 | 33 | 7148 | |||
| 2024-09-20 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000076 | 001-37355 | 241313514 | 33 | 6120 | |||
| 2024-08-22 | 4 | 4 | 0000950170-24-099982 | 8392 | ||||||
| 2024-08-22 | 4 | 4 | 0000950170-24-099980 | 8658 | ||||||
| 2024-08-21 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000075 | 001-37355 | 241229098 | 33 | 5549 | |||
| 2024-08-21 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000074 | 001-37355 | 241228951 | 33 | 5523 | |||
| 2024-08-19 | 4 | 4 | 0000950170-24-098803 | 12859 | ||||||
| 2024-08-19 | 4 | 4 | 0000950170-24-098799 | 18471 | ||||||
| 2024-08-19 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000073 | 001-37355 | 241222323 | 33 | 5456 | |||
| 2024-08-19 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000072 | 001-37355 | 241222298 | 33 | 4932 | |||
| 2024-08-14 | 4 | 4 | 0000950170-24-097325 | 10619 | ||||||
| 2024-08-14 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000070 | 001-37355 | 241208855 | 33 | 4360 | |||
| 2024-08-07 | SC 13G/A | us92686j1060_080724.txt | 0001086364-24-008371 | 005-88828 | 241183804 | 34 | 13241 | |||
| 2024-07-31 | 4 | 4 | 0000950170-24-088538 | 12688 | ||||||
| 2024-07-31 | 4 | 4 | 0000950170-24-088544 | 12675 | ||||||
| 2024-07-31 | 4 | 4 | 0000950170-24-088537 | 10723 | ||||||
| 2024-07-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005692 | 001-37355 | 241159181 | 33 | 4714 | |||
| 2024-07-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005691 | 001-37355 | 241159173 | 33 | 4718 | |||
| 2024-07-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005690 | 001-37355 | 241159166 | 33 | 4699 | |||
| 2024-07-24 | 10-Q | 10-Q | 0000950170-24-086111 | 001-37355 | 241138852 | 34 | 9107853 | 1 | 1 | |
| 2024-07-24 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-086039 | 001-37355 | 241138179 | 34 | 432863 | 1 | 1 |
| 2024-06-04 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-068297 | 001-37355 | 241016068 | 34 | 314923 | 1 | 1 |
| 2024-05-23 | 8-K | 8-K | 5.02,5.07,9.01 | 0000950170-24-063707 | 001-37355 | 24974944 | 34 | 205147 | 1 | 1 |
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063705 | 333-223503 | 24974924 | 33 | 141378 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063698 | 333-211270 | 24974870 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063697 | 333-203810 | 24974867 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063691 | 333-230247 | 24974855 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063690 | 333-216857 | 24974851 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063689 | 333-236666 | 24974848 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063685 | 333-269675 | 24974834 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063684 | 333-276939 | 24974831 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063683 | 333-253219 | 24974829 | 33 | 288329 | |||
| 2024-05-23 | S-8 POS | S-8 POS | 0000950170-24-063677 | 333-262609 | 24974810 | 33 | 288329 | |||
| 2024-05-22 | S-8 POS | S-8 POS | 0000950170-24-063590 | 333-223503 | 24974295 | 33 | 284369 | |||
| 2024-05-22 | S-8 | S-8 | 0000950170-24-063533 | 333-279633 | 24973829 | 33 | 785979 | |||
| 2024-05-03 | 4 | FORM 4 SUBMISSION | 0001209191-24-005522 | 19715 | ||||||
| 2024-05-03 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000054 | 001-37355 | 24912952 | 33 | 7428 | |||
| 2024-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-24-005486 | 33555 | ||||||
| 2024-05-01 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000052 | 001-37355 | 24902865 | 33 | 6482 | |||
| 2024-04-25 | 10-Q | 10-Q | 0000950170-24-047833 | 001-37355 | 24872473 | 34 | 7279387 | 1 | 1 | |
| 2024-04-24 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-047567 | 001-37355 | 24870541 | 34 | 377788 | 1 | 1 |
| 2024-04-05 | ARS | ARS | 0000950170-24-042275 | 001-37355 | 24826686 | 34 | 792947 | |||
| 2024-04-05 | DEFA14A | DEFA14A | 0000950170-24-042264 | 001-37355 | 24826564 | 34 | 253943 | |||
| 2024-04-05 | DEF 14A | DEF 14A | 0000950170-24-042251 | 001-37355 | 24826464 | 34 | 3370788 | 1 | 1 | |
| 2024-03-27 | 4 | FORM 4 SUBMISSION | 0001209191-24-005118 | 6904 | ||||||
| 2024-03-27 | 4 | FORM 4 SUBMISSION | 0001209191-24-005117 | 6889 | ||||||
| 2024-03-27 | 4 | FORM 4 SUBMISSION | 0001209191-24-005116 | 6907 | ||||||
| 2024-03-26 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-036151 | 001-37355 | 24780882 | 34 | 261117 | 1 | 1 |
| 2024-03-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-004233 | 6888 | ||||||
| 2024-03-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-004232 | 6903 | ||||||
| 2024-03-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-004231 | 6906 | ||||||
| 2024-03-04 | 8-K | 8-K | 8.01,9.01 | 0000950170-24-024878 | 001-37355 | 24715510 | 34 | 204270 | 1 | 1 |
| 2024-03-01 | 424B5 | 424B5 | 0000950170-24-023848 | 333-273460 | 24709871 | 33 | 834802 | |||
| 2024-03-01 | 8-K | 8-K | 1.01,8.01,9.01 | 0000950170-24-023838 | 001-37355 | 24709566 | 34 | 619159 | 1 | 1 |
| 2024-02-27 | 424B5 | 424B5 | 0000950170-24-021420 | 333-273460 | 24688616 | 33 | 807556 | |||
| 2024-02-27 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-020616 | 001-37355 | 24681925 | 34 | 261097 | 1 | 1 |
| 2024-02-14 | SC 13G/A | sayw24021420_13ga.htm | 0000905148-24-000616 | 005-88828 | 24633550 | 34 | 288709 | |||
| 2024-02-13 | SC 13G | SCHEDULE 13G | 0001104659-24-022246 | 005-88828 | 24629911 | 34 | 13037 | |||
| 2024-02-09 | 4 | FORM 4 SUBMISSION | 0001209191-24-003068 | 4933 | ||||||
| 2024-02-09 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000023 | 001-37355 | 24614629 | 33 | 6117 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001571 | 005-88828 | 24612644 | 34 | 8262 | |||
| 2024-02-08 | 4 | FORM 4 SUBMISSION | 0001209191-24-003010 | 21388 | ||||||
| 2024-02-08 | 4 | FORM 4 SUBMISSION | 0001209191-24-003008 | 8697 | ||||||
| 2024-02-08 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000022 | 001-37355 | 24609921 | 33 | 8096 | |||
| 2024-02-08 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000021 | 001-37355 | 24609601 | 33 | 4941 | |||
| 2024-02-07 | S-8 | S-8 | 0000950170-24-012328 | 333-276939 | 24605998 | 33 | 174395 | |||
| 2024-02-07 | 10-K | 10-K | 0000950170-24-012322 | 001-37355 | 24605905 | 34 | 10701136 | 1 | 1 | |
| 2024-02-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-012199 | 001-37355 | 24604369 | 34 | 379095 | 1 | 1 |
| 2024-01-31 | 4 | FORM 4 SUBMISSION | 0001209191-24-002512 | 10552 | ||||||
| 2024-01-31 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000020 | 001-37355 | 24584088 | 33 | 5443 | |||
| 2024-01-30 | 4 | FORM 4 SUBMISSION | 0001209191-24-002458 | 8957 | ||||||
| 2024-01-30 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000019 | 001-37355 | 24578504 | 33 | 4358 | |||
| 2024-01-26 | SC 13G | us92686j1060_012624.txt | 0001086364-24-004283 | 005-88828 | 24565760 | 34 | 13668 | |||
| 2024-01-24 | SC 13G/A | VikingTherapeutics.txt | 0000093751-24-000183 | 005-88828 | 24555549 | 34 | 8461 | |||
| 2024-01-19 | 4 | FORM 4 SUBMISSION | 0001209191-24-001973 | 8701 | ||||||
| 2024-01-19 | 144 | xsl144X01/primary_doc.xml | 0000103623-24-000011 | 001-37355 | 24546094 | 33 | 4364 | |||
| 2024-01-12 | SC 13G/A | VKTX_SC13GA1.htm | 0001273087-24-000012 | 005-88828 | 24532353 | 34 | 81662 | |||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000931 | 14781 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000930 | 14745 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000929 | 16824 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000925 | 5224 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000924 | 5225 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000923 | 5248 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000922 | 5254 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000921 | 5230 | ||||||
| 2024-01-04 | 144 | xsl144X01/primary_doc.xml | 0001217234-24-000004 | 001-37355 | 24514156 | 33 | 4279 | |||
| 2023-11-02 | SC 13G | SC 13G | 0001140361-23-051165 | 005-88828 | 231372897 | 34 | 285515 | |||
| 2023-10-25 | 10-Q | 10-Q | 0000950170-23-055259 | 001-37355 | 231346672 | 34 | 9119405 | 1 | 1 | |
| 2023-10-25 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-055209 | 001-37355 | 231346313 | 34 | 514413 | 1 | 1 |
| 2023-07-26 | S-3ASR | S-3ASR | 0000950170-23-034818 | 333-273460 | 231114642 | 33 | 2238615 | |||
| 2023-07-26 | 10-Q | 10-Q | 0000950170-23-034773 | 001-37355 | 231114177 | 34 | 10237171 | 1 | 1 | |
| 2023-07-26 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-034741 | 001-37355 | 231113912 | 34 | 591999 | 1 | 1 |
| 2023-06-14 | 8-K | 8-K | 5.07,9.01 | 0000950170-23-027965 | 001-37355 | 231014417 | 34 | 229543 | 1 | 1 |
| 2023-05-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-030796 | 8581 | ||||||
| 2023-05-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-030794 | 8610 | ||||||
| 2023-05-16 | 144 | xsl144X01/primary_doc.xml | 0001976408-23-000005 | 001-37355 | 23928888 | 33 | 4123 | |||
| 2023-05-16 | 144 | xsl144X01/primary_doc.xml | 0001976408-23-000004 | 001-37355 | 23928188 | 33 | 5343 | |||
| 2023-05-11 | 8-K | 8-K | 5.03,9.01 | 0000950170-23-021359 | 001-37355 | 23911985 | 34 | 472849 | 1 | 1 |
| 2023-05-01 | 4 | FORM 4 SUBMISSION | 0001209191-23-026356 | 4829 | ||||||
| 2023-05-01 | ARS | ARS | 0000950170-23-016267 | 001-37355 | 23874027 | 34 | 597176 | |||
| 2023-05-01 | DEFA14A | DEFA14A | 0000950170-23-016264 | 001-37355 | 23874000 | 34 | 260551 | |||
| 2023-05-01 | DEF 14A | DEF 14A | 0000950170-23-016221 | 001-37355 | 23873437 | 34 | 3919537 | 1 | 1 | |
| 2023-05-01 | 144 | xsl144X01/primary_doc.xml | 0001607678-23-000003 | 001-37355 | 23872438 | 33 | 7696 | |||
| 2023-04-26 | 10-Q | 10-Q | 0000950170-23-014883 | 001-37355 | 23850624 | 34 | 8939599 | 1 | 1 | |
| 2023-04-26 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-014788 | 001-37355 | 23849730 | 34 | 487122 | 1 | 1 |
| 2023-04-24 | 4 | FORM 4 SUBMISSION | 0001209191-23-025473 | 8612 | ||||||
| 2023-04-24 | 144 | xsl144X01/primary_doc.xml | 0001607678-23-000002 | 001-37355 | 23840666 | 33 | 4888 | |||
| 2023-04-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-025277 | 4829 | ||||||
| 2023-04-19 | 144 | xsl144X01/primary_doc.xml | 0001607678-23-000001 | 001-37355 | 23830583 | 33 | 7214 | |||
| 2023-04-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-024725 | 8841 | ||||||
| 2023-04-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-024724 | 8846 | ||||||
| 2023-04-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-024723 | 8968 | ||||||
| 2023-04-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-024722 | 8967 | ||||||
| 2023-04-17 | 144 | xsl144X01/primary_doc.xml | 0001838112-23-000005 | 001-37355 | 23825000 | 33 | 6506 | |||
| 2023-04-17 | 144 | xsl144X01/primary_doc.xml | 0001838112-23-000004 | 001-37355 | 23824966 | 33 | 8200 | |||
| 2023-04-17 | 144 | xsl144X01/primary_doc.xml | 0001838112-23-000003 | 001-37355 | 23824928 | 33 | 4220 | |||
| 2023-04-17 | 144 | xsl144X01/primary_doc.xml | 0001838112-23-000002 | 001-37355 | 23824845 | 33 | 6984 | |||
| 2023-04-17 | 144 | xsl144X01/primary_doc.xml | 0001838112-23-000001 | 001-37355 | 23824686 | 33 | 5239 | |||
| 2023-04-17 | PRE 14A | PRE 14A | 0000950170-23-013104 | 001-37355 | 23824640 | 34 | 3922658 | 1 | 1 | |
| 2023-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-23-024228 | 8678 | ||||||
| 2023-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-23-024227 | 30363 | ||||||
| 2023-04-10 | SC 13G | filing.txt | 0000315066-23-002238 | 005-88828 | 23809898 | 34 | 8189 | |||
| 2023-04-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-022400 | 25261 | ||||||
| 2023-04-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-022398 | 29893 | ||||||
| 2023-04-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-022396 | 20422 | ||||||
| 2023-04-03 | 8-K | 8-K | 8.01,9.01 | 0000950170-23-011636 | 001-37355 | 23793894 | 34 | 232640 | 1 | 1 |
| 2023-03-31 | 8-K | 8-K | 1.01,8.01,9.01 | 0000950170-23-011443 | 001-37355 | 23789337 | 34 | 715927 | 1 | 1 |
| 2023-03-31 | 424B5 | 424B5 | 0000950170-23-011441 | 333-258231 | 23789293 | 33 | 1039888 | |||
| 2023-03-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-021743 | 41625 | ||||||
| 2023-03-30 | SC 13D/A | SC 13D/A | 0001193125-23-085535 | 005-88828 | 23780756 | 34 | 32595 | |||
| 2023-03-29 | 424B5 | 424B5 | 0000950170-23-010583 | 333-258231 | 23775135 | 33 | 1071490 | |||
| 2023-03-28 | 8-K | 8-K | 7.01,9.01 | 0000950170-23-010112 | 001-37355 | 23766128 | 34 | 226139 | 1 | 1 |
| 2023-03-28 | 8-K | 8-K | 7.01,9.01 | 0000950170-23-010108 | 001-37355 | 23766102 | 34 | 299731 | 1 | 1 |
| 2023-02-14 | SC 13G/A | arrowmark-vktx123122a5.htm | 0001172661-23-001442 | 005-88828 | 23632002 | 34 | 54166 | |||
| 2023-02-10 | S-8 | S-8 | 0001564590-23-001696 | 333-269675 | 23608294 | 33 | 163615 | |||
| 2023-02-10 | 10-K | 10-K | 0001564590-23-001685 | 001-37355 | 23607614 | 34 | 10929072 | 1 | 1 | |
| 2023-02-09 | SC 13D/A | SC 13D/A | 0001193125-23-030129 | 005-88828 | 23606699 | 34 | 56957 | |||
| 2023-02-08 | 8-K | 8-K | 2.02,9.01 | 0001564590-23-001611 | 001-37355 | 23599194 | 34 | 502867 | 1 | 1 |
| 2023-02-03 | SC 13G/A | Viking_Therapeutics_Inc.txt | 0000093751-23-000183 | 005-88828 | 23585555 | 34 | 8244 | |||
| 2023-01-17 | 4 | FORM 4 SUBMISSION | 0001209191-23-003606 | 4846 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001343 | 14865 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001342 | 14861 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001340 | 14850 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001314 | 5109 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001313 | 5110 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001311 | 5139 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001310 | 5133 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-001297 | 5115 | ||||||
| 2023-01-03 | SC 13G | VKTX_SC13G.htm | 0001273087-23-000003 | 005-88828 | 23502870 | 34 | 81560 | |||
| 2022-10-26 | 10-Q | 10-Q | 0001564590-22-035295 | 001-37355 | 221334057 | 34 | 9080900 | 1 | 1 | |
| 2022-10-26 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-035271 | 001-37355 | 221333626 | 34 | 495478 | 1 | 1 |
| 2022-07-27 | 10-Q | 10-Q | 0001564590-22-026717 | 001-37355 | 221111790 | 34 | 9226804 | 1 | 1 | |
| 2022-07-27 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-026689 | 001-37355 | 221111138 | 34 | 517385 | 1 | 1 |
| 2022-07-08 | SC 13G | us92686j1060_070822.txt | 0000834237-22-010314 | 005-88828 | 221075073 | 34 | 12166 | |||
| 2022-05-26 | 8-K | 8-K | 5.07 | 0001564590-22-021417 | 001-37355 | 22970044 | 34 | 183319 | 1 | 1 |
| 2022-05-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-026674 | 4501 | ||||||
| 2022-04-27 | 10-Q | 10-Q | 0001564590-22-016129 | 001-37355 | 22860718 | 34 | 7854917 | 1 | 1 | |
| 2022-04-27 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-016110 | 001-37355 | 22860477 | 34 | 446636 | 1 | 1 |
| 2022-04-07 | DEFA14A | DEFA14A | 0001564590-22-013879 | 001-37355 | 22814557 | 34 | 2266740 | |||
| 2022-04-07 | DEF 14A | DEF 14A | 0001564590-22-013875 | 001-37355 | 22814538 | 34 | 970839 | |||
| 2022-02-14 | SC 13G/A | arrowmark-vktx123121a4.htm | 0001172661-22-000676 | 005-88828 | 22629910 | 34 | 53978 | |||
| 2022-02-14 | SC 13G/A | VIKING_THERAPEUTICS_INC.txt | 0000093751-22-000363 | 005-88828 | 22624240 | 34 | 8393 | |||
| 2022-02-11 | 4 | FORM 4 SUBMISSION | 0001209191-22-008999 | 4844 | ||||||
| 2022-02-09 | S-8 | S-8 | 0001564590-22-004440 | 333-262609 | 22608406 | 33 | 162353 | |||
| 2022-02-09 | 10-K | 10-K | 0001564590-22-004429 | 001-37355 | 22608030 | 34 | 10573554 | 1 | 1 | |
| 2022-02-09 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-004406 | 001-37355 | 22607387 | 34 | 561283 | 1 | 1 |
| 2022-02-03 | SC 13G/A | us92686j1060_020322.txt | 0000834237-22-006335 | 005-88828 | 22589053 | 34 | 13272 | |||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001988 | 10861 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001987 | 10873 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001986 | 10861 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001985 | 5094 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001983 | 5095 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001982 | 5118 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001981 | 5124 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-22-001980 | 5100 | ||||||
| 2021-11-03 | 10-Q | 10-Q | 0001564590-21-054030 | 001-37355 | 211376348 | 34 | 9019413 | 1 | 1 | |
| 2021-11-03 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-053950 | 001-37355 | 211375439 | 34 | 514602 | 1 | 1 |
| 2021-09-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-058253 | 6947 | ||||||
| 2021-09-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-058249 | 6962 | ||||||
| 2021-09-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-058246 | 6961 | ||||||
| 2021-08-11 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-08-11 16:30:00 | 9999999995-21-003155 | 333-258231 | 211165414 | 33 | 1696 | ||
| 2021-08-11 | 424B5 | 424B5 | 0001564590-21-043489 | 333-258231 | 211164135 | 33 | 256752 | |||
| 2021-08-05 | CORRESP | filename1.htm | 0001564590-21-041580 | 36920 | ||||||
| 2021-08-02 | UPLOAD | filename1.pdf | 0000000000-21-009419 | 40202 | ||||||
| 2021-07-28 | 8-K | 8-K | 1.01,1.02,9.01 | 0001564590-21-038678 | 001-37355 | 211123610 | 34 | 170392 | 1 | 1 |
| 2021-07-28 | S-3 | S-3 | 0001564590-21-038667 | 333-258231 | 211123211 | 33 | 1674238 | |||
| 2021-07-28 | 10-Q | 10-Q | 0001564590-21-038663 | 001-37355 | 211123138 | 34 | 8867384 | 1 | 1 | |
| 2021-07-28 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-038623 | 001-37355 | 211122671 | 34 | 500466 | 1 | 1 |
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0001209191-21-039521 | 4485 | ||||||
| 2021-05-21 | 8-K | 8-K | 5.07 | 0001564590-21-029335 | 001-37355 | 21949896 | 34 | 196412 | 1 | 1 |
| 2021-04-28 | 10-Q | 10-Q | 0001564590-21-021430 | 001-37355 | 21865176 | 34 | 7788754 | 1 | 1 | |
| 2021-04-28 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-021350 | 001-37355 | 21864338 | 34 | 424121 | 1 | 1 |
| 2021-04-08 | DEFA14A | DEFA14A | 0001564590-21-018184 | 001-37355 | 21815240 | 34 | 1044780 | |||
| 2021-04-08 | DEF 14A | DEF 14A | 0001564590-21-018175 | 001-37355 | 21815085 | 34 | 2042699 | |||
| 2021-04-08 | 25-NSE | xslF25X02/primary_doc.xml | 0001354457-21-000458 | 001-37355 | 21814997 | 34 | 2952 | |||
| 2021-03-25 | 4 | FORM 4 SUBMISSION | 0001209191-21-023130 | 6698 | ||||||
| 2021-02-17 | S-8 | S-8 | 0001564590-21-006421 | 333-253219 | 21645995 | 33 | 162016 | |||
| 2021-02-17 | 10-K | 10-K | 0001564590-21-006406 | 001-37355 | 21645599 | 34 | 10186460 | 1 | 1 | |
| 2021-02-17 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-006376 | 001-37355 | 21644853 | 34 | 542214 | 1 | 1 |
| 2021-02-16 | SC 13G/A | 13G/A | 0001172661-21-000652 | 005-88828 | 21635603 | 34 | 53988 | |||
| 2021-02-11 | SC 13G | Viking_Therapeutics_Inc.txt | 0000093751-21-000322 | 005-88828 | 21619899 | 34 | 10282 | |||
| 2021-02-01 | SC 13G/A | us92686j1060_013121.txt | 0000834237-21-005734 | 005-88828 | 21574727 | 34 | 13254 | |||
| 2021-01-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-004101 | 4836 | ||||||
| 2021-01-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-004098 | 6429 | ||||||
| 2021-01-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-004095 | 4822 | ||||||
| 2021-01-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-004093 | 4817 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002140 | 5095 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002135 | 5124 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002128 | 5100 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002124 | 5094 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002119 | 5118 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002114 | 11201 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002104 | 13009 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002086 | 11036 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-21-002074 | 11036 | ||||||
| 2021-01-06 | 3 | FORM 3 SUBMISSION | 0001209191-21-002053 | 16305 | ||||||
| 2021-01-06 | 3 | FORM 3 SUBMISSION | 0001209191-21-002036 | 27294 | ||||||
| 2021-01-06 | 8-K | 8-K | 5.02,9.01 | 0001564590-21-000409 | 001-37355 | 21510729 | 34 | 214792 | 1 | 1 |
| 2020-10-28 | 10-Q | 10-Q | 0001564590-20-048398 | 001-37355 | 201269409 | 34 | 8525742 | 1 | 1 | |
| 2020-10-28 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-048337 | 001-37355 | 201268747 | 34 | 531280 | 1 | 1 |
| 2020-09-16 | 4 | FORM 4 SUBMISSION | 0001209191-20-050734 | 6887 | ||||||
| 2020-09-16 | 4 | FORM 4 SUBMISSION | 0001209191-20-050732 | 6900 | ||||||
| 2020-08-28 | SC 13D/A | SC 13D/A | 0001193125-20-234860 | 005-88828 | 201148778 | 34 | 54812 | |||
| 2020-08-28 | 4/A | FORM 4/A SUBMISSION | 0000899243-20-023644 | 5831 | ||||||
| 2020-08-27 | 4 | FORM 4 SUBMISSION | 0000899243-20-023546 | 7065 | ||||||
| 2020-07-29 | 10-Q | 10-Q | 0001564590-20-034329 | 001-37355 | 201057866 | 34 | 8370994 | 1 | 1 | |
| 2020-07-29 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-034308 | 001-37355 | 201057600 | 34 | 533726 | 1 | 1 |
| 2020-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-20-039521 | 4485 | ||||||
| 2020-05-21 | 8-K | 8-K | 5.07 | 0001564590-20-026582 | 001-37355 | 20902648 | 34 | 46591 | ||
| 2020-05-20 | DEFA14A | DEFA14A | 0001564590-20-026393 | 001-37355 | 20898488 | 34 | 42489 | |||
| 2020-04-30 | 10-Q | 10-Q | 0001564590-20-020233 | 001-37355 | 20836559 | 34 | 6483165 | 1 | ||
| 2020-04-30 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-020180 | 001-37355 | 20835753 | 34 | 273132 | ||
| 2020-04-06 | DEFA14A | DEFA14A | 0001564590-20-015533 | 001-37355 | 20777452 | 34 | 858840 | |||
| 2020-04-06 | DEF 14A | DEF 14A | 0001564590-20-015522 | 001-37355 | 20777309 | 34 | 1823936 | |||
| 2020-04-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-023378 | 5364 | ||||||
| 2020-03-17 | 8-K | 8-K | 7.01 | 0001564590-20-011413 | 001-37355 | 20721235 | 34 | 26200 | ||
| 2020-02-26 | S-8 | S-8 | 0001564590-20-006838 | 333-236666 | 20656906 | 33 | 152514 | |||
| 2020-02-26 | 10-K | 10-K | 0001564590-20-006766 | 001-37355 | 20655596 | 34 | 9031960 | 1 | ||
| 2020-02-19 | CT ORDER | filename1.pdf | 20200219,20200219 | 9999999997-20-000814 | 333-197182 | 20630410 | 33 | 122148 | ||
| 2020-02-14 | SC 13G/A | SCHEDULE 13G HOLDINGS REPORT AMENDMENT | 0001172661-20-000911 | 005-88828 | 20621133 | 34 | 54023 | |||
| 2020-02-13 | SC 13G/A | VikingTherapeut.txt | 0000093751-20-000478 | 005-88828 | 20611140 | 34 | 8498 | |||
| 2020-02-07 | SC 13G/A | filing.txt | 0000315066-20-001268 | 005-88828 | 20586011 | 34 | 8435 | |||
| 2020-02-06 | SC 13G/A | us92686j1060_020520.txt | 0000834237-20-006932 | 005-88828 | 20581421 | 34 | 13224 | |||
| 2020-01-21 | 4 | FORM 4 SUBMISSION | 0001209191-20-004314 | 4830 | ||||||
| 2020-01-21 | 4 | FORM 4 SUBMISSION | 0001209191-20-004311 | 5029 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001428 | 5364 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001426 | 9298 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001425 | 5136 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001422 | 5094 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001421 | 5100 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001420 | 5124 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001419 | 5095 | ||||||
| 2020-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-20-001418 | 5118 | ||||||
| 2019-11-05 | 10-Q | 10-Q | 0001564590-19-040424 | 001-37355 | 191193774 | 34 | 7480469 | 1 | ||
| 2019-11-05 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-040059 | 001-37355 | 191191737 | 34 | 345533 | ||
| 2019-10-31 | 4 | FORM 4 SUBMISSION | 0001209191-19-054654 | 5362 | ||||||
| 2019-10-10 | SC 13G/A | SCHEDULE 13G HOLDINGS REPORT AMENDMENT | 0001172661-19-002034 | 005-88828 | 191146231 | 34 | 54026 | |||
| 2019-08-02 | 4 | FORM 4 SUBMISSION | 0001209191-19-044336 | 5361 | ||||||
| 2019-08-02 | 8-K | 8-K | 1.01,9.01 | 0001564590-19-028063 | 001-37355 | 19993864 | 34 | 281114 | ||
| 2019-08-02 | 424B5 | 424B5 | 0001564590-19-028058 | 333-226133 | 19993784 | 33 | 608568 | |||
| 2019-08-01 | 10-Q | 10-Q | 0001564590-19-028043 | 001-37355 | 19993609 | 34 | 7471376 | 1 | ||
| 2019-08-01 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-027983 | 001-37355 | 19993041 | 34 | 346962 | ||
| 2019-07-02 | 4 | FORM 4 SUBMISSION | 0001209191-19-040272 | 5089 | ||||||
| 2019-07-02 | 3 | FORM 3 SUBMISSION | 0001209191-19-040257 | 6099 | ||||||
| 2019-07-02 | 8-K | 8-K | 5.02,9.01 | 0001564590-19-024412 | 001-37355 | 19937506 | 34 | 56030 | ||
| 2019-05-23 | 8-K | 8-K | 5.07 | 0001564590-19-020346 | 001-37355 | 19850790 | 34 | 47113 | ||
| 2019-05-02 | 10-Q | 10-Q | 0001564590-19-015390 | 001-37355 | 19792952 | 34 | 6930359 | 1 | ||
| 2019-05-02 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-015327 | 001-37355 | 19791875 | 34 | 289960 | ||
| 2019-04-10 | SC 13G/A | VIKING THERAPEUTICS, INC. | 0000093751-19-000378 | 005-88828 | 19741334 | 34 | 10542 | |||
| 2019-04-05 | DEFA14A | DEFA14A | 0001564590-19-010933 | 001-37355 | 19735607 | 34 | 412489 | |||
| 2019-04-05 | DEF 14A | DEF 14A | 0001564590-19-010928 | 001-37355 | 19735420 | 34 | 1258716 | |||
| 2019-03-13 | S-8 | S-8 | 0001564590-19-007589 | 333-230247 | 19679381 | 33 | 149177 | |||
| 2019-03-13 | 10-K | 10-K | 0001564590-19-007584 | 001-37355 | 19678832 | 34 | 9719100 | 1 | ||
| 2019-03-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-007569 | 001-37355 | 19678385 | 34 | 335556 | ||
| 2019-02-14 | SC 13G/A | SC 13G/A | 0001193125-19-040832 | 005-88828 | 19606382 | 34 | 52618 | |||
| 2019-02-14 | SC 13G | arrowmark-vktx123118.htm | 0001172661-19-000513 | 005-88828 | 19600818 | 34 | 53946 | |||
| 2019-02-13 | SC 13G/A | SC 13G/A | 0001178913-19-000440 | 005-88828 | 19598522 | 34 | 137539 | |||
| 2019-02-13 | SC 13G/A | filing.txt | 0000315066-19-001442 | 005-88828 | 19595267 | 34 | 8389 | |||
| 2019-02-13 | SC 13G | VIKING THERAPEUTICS, INC. | 0000093751-19-000115 | 005-88828 | 19593839 | 34 | 10548 | |||
| 2019-02-08 | SC 13G | us92686j1060_020719.txt | 0000215457-19-006859 | 005-88828 | 19576668 | 34 | 13157 | |||
| 2019-01-22 | 4 | FORM 4 SUBMISSION | 0001209191-19-004861 | 4817 |
One latest value per concept from companyfacts (270 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 127.52M | 2026-10-15 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 2.98B | 2025-06-30 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 43,674.12 | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| ffd | NrrtvMaxAggtAmt | NrrtvMaxAggtAmt | shares | 9.04M | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| ffd | NrrtvMaxAggtOfferingPric | NrrtvMaxAggtOfferingPric | USD | 316.25M | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 43,674.12 | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 316.25M | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-09-24 | 424B5 | 2026-09-25 | 0001193125-26-401384 | |||
| srt | StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased | StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased | shares | 633,810 | 2015-05-31 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 82.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 2.97M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | USD | -1.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 1.91B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | USD | 456,412 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition | USD | 39.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 2.60M | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | AmortizationOfDebtDiscountPremium | Amortization of Debt Discount (Premium) | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 12.65M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | Assets | Assets | USD | 977.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 973.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 835.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 1,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 1.22M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 283.43M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AvailableForSaleSecurities | Available-for-sale Securities | USD | 13.34M | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | USD | 416 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-10 | 0001564590-16-018987 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | USD | 611 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-10 | 0001564590-16-018987 | |
| us-gaap | AvailableForSaleSecuritiesAmortizedCost | Available-for-sale Securities, Amortized Cost Basis | USD | 11.61M | 2017-12-31 | 2018 | Q2 | 10-Q | 2018-08-09 | 0001564590-18-021125 | |
| us-gaap | AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | USD | 19,000 | 2017-12-31 | 2018 | Q2 | 10-Q | 2018-08-09 | 0001564590-18-021125 | |
| us-gaap | AvailableForSaleSecuritiesCurrent | Available-for-sale Securities, Current | USD | 204.87M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 282.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 282.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear | Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year | Security | 117 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-09 | 0001564590-18-021125 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 677.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CashAndCashEquivalentsFairValueDisclosure | Cash and Cash Equivalents, Fair Value Disclosure | USD | 553.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -5.66M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-01 | 0001564590-19-028043 |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | USD | 8.74M | 2015-01-01 | 2015-06-30 | 2015 | Q2 | 10-Q | 2015-08-14 | 0001193125-15-291529 |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 11.25M | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-10 | 0001564590-16-018987 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 36.63M | 2022-12-31 | 2022 | FY | 10-K | 2023-02-10 | 0001564590-23-001685 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 677.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | USD | 512.01M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 32.90M | 2023-01-01 | 2023-06-30 | 2023 | Q2 | 10-Q | 2023-07-26 | 0000950170-23-034773 |
| us-gaap | CashFDICInsuredAmount | Cash, FDIC Insured Amount | USD | 250,000 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-06-12 | 0001193125-15-220837 | |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 1.5 | 2016-04-13 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 | |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 7.50M | 2016-04-13 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 7.50M | 2016-04-13 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001564590-17-022829 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 23.58M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 300.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 127.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 127.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 1,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -471.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ConvertibleLongTermNotesPayable | Convertible Notes Payable, Noncurrent | USD | 250.66M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ConvertibleNotesPayableCurrent | Convertible Notes Payable, Current | USD | 3.45M | 2017-12-31 | 2018 | FY | 10-K | 2019-03-13 | 0001564590-19-007584 | |
| us-gaap | CurrentFederalStateAndLocalTaxExpenseBenefit | Current Federal, State and Local, Tax Expense (Benefit) | USD | 1,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 1,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 456,412 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-21 | 0001564590-17-004911 |
| us-gaap | DebtConversionConvertedInstrumentSharesIssued1 | Debt Conversion, Converted Instrument, Shares Issued | shares | 57,046 | 2015-05-03 | 2015-05-04 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | DebtInstrumentInterestRateDuringPeriod | Debt Instrument, Interest Rate During Period | pure | 0.05 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-13 | 0001564590-19-007584 |
| us-gaap | DebtInstrumentInterestRateStatedPercentage | Debt Instrument, Interest Rate, Stated Percentage | pure | 0.05 | 2016-12-31 | 2017 | Q1 | 10-Q | 2017-05-10 | 0001564590-17-010332 | |
| us-gaap | DebtSecuritiesAvailableForSaleGainLoss | Debt Securities, Available-for-sale, Gain (Loss) | USD | 0 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-04-30 | 0001193125-26-193315 |
| us-gaap | DebtSecuritiesAvailableForSaleRealizedGainLoss | Debt Securities, Available-for-sale, Realized Gain (Loss) | USD | 30,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions | Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | Security | 113 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance | Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance | shares | 1.00M | 2014-02-28 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | DeferredCompensationArrangementWithIndividualExercisePrice | Deferred Compensation Arrangement with Individual, Exercise Price | USD/shares | 0.01 | 2014-02-01 | 2014-02-28 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | -60.36M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | DeferredFederalStateAndLocalTaxExpenseBenefit | Deferred Federal, State and Local, Tax Expense (Benefit) | USD | -100.67M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | DeferredFinanceCostsNoncurrentNet | Debt Issuance Costs, Noncurrent, Net | USD | 158,842 | 2016-06-30 | 2016 | Q2 | 10-Q | 2016-08-11 | 0001564590-16-024067 | |
| us-gaap | DeferredForeignIncomeTaxExpenseBenefit | Deferred Foreign Income Tax Expense (Benefit) | USD | -19.56M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | DeferredRentCreditNoncurrent | Deferred Rent Credit, Noncurrent | USD | 12,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | -20.76M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | DeferredTaxAssetsGoodwillAndIntangibleAssets | Deferred Tax Assets, Goodwill and Intangible Assets | USD | 134.13M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 264.98M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 247,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 68.18M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsDomestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | USD | 194.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsForeign | Deferred Tax Assets, Operating Loss Carryforwards, Foreign | USD | 156.10M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | USD | 110.60M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | USD | 17.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 58.26M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 4.24M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 174,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 264.74M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 247,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DeferredTaxLiabilitiesOther | Deferred Tax Liabilities, Other | USD | 223,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | DepositsAssetsNoncurrent | Deposits Assets, Noncurrent | USD | 113,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -4.03 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.21 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-04-27 | 0001564590-22-016129 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -4.03 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.17 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | 0 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-21 | 0001564590-17-004911 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.01 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.06 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxExemptIncome | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | -10,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 62,000 | 2015-05-31 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense | Share-based Payment Arrangement, Expense, Tax Benefit | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | FinanceLeaseLiability | Finance Lease, Liability | USD | 0 | 2019-01-01 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 | |
| us-gaap | FinancialLiabilitiesFairValueDisclosure | Financial Liabilities Fair Value Disclosure | USD | 1.40M | 2017-12-31 | 2018 | FY | 10-K | 2019-03-13 | 0001564590-19-007584 | |
| us-gaap | ForeignCurrencyTransactionGainBeforeTax | Foreign Currency Transaction Gain, before Tax | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | -9,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ForeignCurrencyTransactionLossBeforeTax | Foreign Currency Transaction Loss, before Tax | USD | 258,000 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-10 | 0001564590-23-001685 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 51.13M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -203.52M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -359.64M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | -156.12M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 1,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 100.67M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -75.52M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 4.22M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 236,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 1,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 22.64M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncomeTaxReconciliationTaxExemptIncome | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount | USD | -565,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 28.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | IncreaseDecreaseInAccountsPayableRelatedParties | Increase (Decrease) in Accounts Payable, Related Parties | USD | -712 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 27.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | IncreaseDecreaseInDepositOtherAssets | Increase (Decrease) in Deposit Assets | USD | -40,659 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001564590-18-004757 |
| us-gaap | IncreaseDecreaseInDeposits | Increase (Decrease) in Deposits | USD | -79,225 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -469,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | IncreaseDecreaseInOtherAccruedLiabilities | Increase (Decrease) in Other Accrued Liabilities | USD | 3.31M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-10-26 | 0001564590-22-035295 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 3.39M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | IncrementalCommonSharesAttributableToConversionOfDebtSecurities | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities | shares | 656,716 | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-05-02 | 0001564590-19-015390 |
| us-gaap | InterestExpense | Interest Expense | USD | 24,000 | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-05-02 | 0001564590-19-015390 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 88,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 10.35M | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-07-29 | 0001193125-26-324219 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 122,739 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001564590-18-004757 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 81,000 | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 |
| us-gaap | InterestPayableCurrent | Interest Payable, Current | USD | 22,000 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-13 | 0001564590-19-007584 | |
| us-gaap | InvestmentIncomeAmortizationOfPremium | Investment Income, Amortization of Premium | USD | 1.22M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-10 | 0001564590-23-001685 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 14.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | InvestmentIncomeNetAmortizationOfDiscountAndPremium | Investment Income, Net, Amortization of Discount and Premium | USD | 5.50M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-10-25 | 0000950170-23-055259 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 116,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 29,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 29,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-05 | 0001564590-19-040424 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 29,000 | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-07-29 | 0001564590-20-034329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 29,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-17 | 0001564590-21-006406 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 87,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 1,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | Liabilities | Liabilities | USD | 388.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 977.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 133.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | LiabilitiesNoncurrent | Liabilities, Noncurrent | USD | 254.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | LiabilityForUncertainTaxPositionsNoncurrent | Liability for Uncertainty in Income Taxes, Noncurrent | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 633.21M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 62.30M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012501 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 256.14M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | -29.63M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012501 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -377.34M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -5.30M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012501 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -469.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -4.92M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-05-02 | 0001564590-19-015390 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersDiluted | Net Income (Loss) Available to Common Stockholders, Diluted | USD | -4.92M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-05-02 | 0001564590-19-015390 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-10-23 | 0000950170-24-116708 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 483.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -483.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 169,000 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-07-27 | 0001564590-22-026717 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 683,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 4.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 24,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 4.01M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 3.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 400,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 116,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 343,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-17 | 0001564590-21-006406 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 29,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-07 | 0001564590-18-028101 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 29,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-05 | 0001564590-19-040424 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 29,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-28 | 0001564590-20-048398 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 29,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 87,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 243,000 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0001564590-21-054030 |
| us-gaap | OperatingLeasesRentExpenseSubleaseRentals1 | Operating Leases, Rent Expense, Sublease Rentals | USD | 19,737 | 2015-07-06 | 2015-07-07 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.09 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 51.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 80,000 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-05 | 0001564590-15-009694 | |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | USD | -9,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -2.07M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | 14.30M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | PaymentsForRepurchaseOfCommonStock | Payments for Repurchase of Common Stock | USD | 6.79M | 2022-01-01 | 2022-12-31 | 2024 | FY | 10-K | 2025-02-26 | 0000950170-25-027824 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 37,000 | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-04-26 | 0000950170-23-014883 |
| us-gaap | PaymentsRelatedToTaxWithholdingForShareBasedCompensation | Payment, Tax Withholding, Share-based Payment Arrangement | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 154.77M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 3.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ProceedsFromConvertibleDebt | Proceeds from Convertible Debt | USD | 251.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 297.27M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | USD | 2.22M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ProceedsFromNotesPayable | Proceeds from Notes Payable | USD | 2.50M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001564590-16-014212 |
| us-gaap | ProceedsFromRepurchaseOfEquity | Proceeds from (Repurchase of) Equity | USD | -38 | 2015-01-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-05 | 0001564590-15-009694 |
| us-gaap | ProceedsFromSaleMaturityAndCollectionsOfInvestments | Proceeds from Sale, Maturity and Collection of Investments | USD | 372.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ProceedsFromSaleOfAvailableForSaleSecurities | Proceeds from Sale of Available-for-sale Securities | USD | 0 | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-09 | 0001564590-18-021125 |
| us-gaap | ProceedsFromSaleOfAvailableForSaleSecuritiesDebt | Proceeds from Sale of Debt Securities, Available-for-sale | USD | 38.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ProceedsFromSaleOfShortTermInvestments | Proceeds from Sale of Short-term Investments | USD | 38.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 300,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-04-24 | 0000950170-25-058129 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 19,609 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001564590-17-022829 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -469.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | RealizedInvestmentGainsLosses | Realized Investment Gains (Losses) | USD | 30,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | RepaymentsOfConvertibleDebt | Repayments of Convertible Debt | USD | 3.83M | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-02-26 | 0001564590-20-006766 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 432.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 202,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -1.32B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | Revenues | Revenues | USD | 0 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012501 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 4.18M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 39.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.855 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.04 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised | shares | 3.62M | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | shares | 951,188 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-04-28 | 0001564590-21-021430 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 81.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 3.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 12.3 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 389.00M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-02-10 | 0001564590-23-001685 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 1.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 24.68 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 96.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 6.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 18.24 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 347,894 | 2015-06-30 | 2015 | Q2 | 10-Q | 2015-08-14 | 0001193125-15-291529 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 8.87 | 2015-06-30 | 2015 | Q2 | 10-Q | 2015-08-14 | 0001193125-15-291529 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 11.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares | 0 | 2015-01-01 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-06-12 | 0001193125-15-220837 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 12.68 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 33.52 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | SharePrice | Share Price | USD/shares | 0.01 | 2016-04-13 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 | |
| us-gaap | SharesIssuedPricePerShare | Shares Issued, Price Per Share | USD/shares | 1.25 | 2016-04-13 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 588.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | USD | 588.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | StockIssued1 | Stock Issued | USD | 1.80M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-13 | 0001564590-19-007584 |
| us-gaap | StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans | Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares | 0 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-04-24 | 0000950170-25-058129 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 0 | 2019-01-01 | 2019-12-31 | 2023 | FY | 10-K | 2024-02-07 | 0000950170-24-012322 |
| us-gaap | StockIssuedDuringPeriodSharesRestrictedStockAwardGross | Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares | 84,000 | 2015-01-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-05 | 0001564590-15-009694 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 146,106 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 1.20M | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001564590-18-004757 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 73,141 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001564590-18-004757 |
| us-gaap | StockIssuedDuringPeriodValueIssuedForServices | Stock Issued During Period, Value, Issued for Services | USD | 28,760 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-21 | 0001564590-17-004911 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 379.57M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | StockIssuedDuringPeriodValueShareBasedCompensationGross | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | USD | 2.22M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | StockRepurchasedDuringPeriodValue | Stock Repurchased During Period, Value | USD | 38 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-21 | 0001564590-17-004911 |
| us-gaap | StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased | Stock Repurchase Program, Number of Shares Authorized to be Repurchased | shares | 633,810 | 2015-05-31 | 2024 | Q1 | 10-Q | 2024-04-25 | 0000950170-24-047833 | |
| us-gaap | StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased | Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased | shares | 366,190 | 2015-05-31 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 | |
| us-gaap | TreasuryStockCommonShares | Treasury Stock, Common, Shares | shares | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | TreasuryStockShares | Treasury Stock, Shares | shares | 2.19M | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-04-26 | 0000950170-23-014883 | |
| us-gaap | TreasuryStockValue | Treasury Stock, Value | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | TreasuryStockValueAcquiredCostMethod | Treasury Stock, Value, Acquired, Cost Method | USD | 6.79M | 2022-01-01 | 2022-12-31 | 2024 | FY | 10-K | 2025-02-26 | 0000950170-25-027824 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-11 | 0001193125-26-046876 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 116.64M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 77.41M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-04-27 | 0001564590-22-016129 |
| us-gaap | WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation | Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation | shares | 30,211 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | WeightedAverageNumberOfSharesIssuedBasic | Weighted Average Number of Shares Issued, Basic | shares | 116.67M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 116.64M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-10-29 | 0001193125-26-436432 |